ORIC-533 Phase 1 shows clinical activity in multiple myeloma; company to seek partner, extends cash runway to 2026

Oric Pharmaceuticals, Inc.

As of Nov 28, 2023, 23 patients dosed (400-2400 mg QD); 100% triple-class refractory, 91% penta-refractory.
No DLTs, dose reductions, or serious TRAEs; only Grade 1-2 TRAEs observed.
Confirmed minor response in a penta-refractory patient who had progressed on anti-BCMA bispecific.
Dose-dependent immune activation (CD8+ T cells, NK cells) at ≥1200 mg; soluble BCMA reductions at 1600 mg.
Company to complete ORIC-533 dose escalation in Q1 2024 then seek partner; focus on ORIC-114 and ORIC-944.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.